Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyeocco Serum Antibodies TPMT Coverage Update | Open…
    Ask Trek AI about this page
    CurrenteoccoPolicy N/A

    Serum Antibodies for Diagnosis of Inflammatory Bowel Disease

    Customize your policy alerts

    Sign up for all eocco policy alerts

    Know when eocco releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage, and coding for serum antibody panels (e.g., ASCA, ANCA), TPMT genotyping/phenotyping, thiopurine metabolite monitoring, and related tests used to diagnose or manage inflammatory bowel disease (IBD). Applies to providers ordering these tests for members of the payer (eocco).

    Policy Summary
    Payereocco
    PolicySerum Antibodies for Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2026
    Next Review DateJun 24, 2026
    Key ActionSubmit prior authorization with specialist chart notes, diagnostic study results, and pathology to support medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50-80%

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ANCA detection rate (UC)
    46-70%ASCA detection rate (CD)
    one lifetimeTPMT baseline covered
    multiplePolicy review history

    Coverage Criteria

    TPMT baseline testing — Covered indications

    Covered when ANY one of the following is met (baseline TPMT genotype testing is covered one time during the patient's lifetime):

    TPMT baseline criteria: a) To determine candidacy for thiopurine treatment prior to initiation of 6-mercaptopurine (6-MP), azathioprine (AZA), or thioguanine (6-TG); OR b) In patients on thiopurine therapy with abnormal CBC results that do not respond to dose reduction.one-time baseline for genotype

    Covered one time during the patient's lifetime

    Thiopurine metabolite monitoring — Covered indications

    Monitoring of thiopurine metabolite levels is considered medically necessary when ANY one of the following indications is met:

    Metabolite monitoring: a) To measure blood levels in individuals suspected of having toxic responses to azathioprine and/or 6-mercaptopurine (e.g., hepatotoxicity or myelotoxicity); OR b) To measure drug levels in individuals who have not responded to therapy.as clinically indicated

    Serologic antibody tests and biologic drug level/antibody tests — Not covered / Experimental or Investigational

    The following tests are considered experimental, investigational, or unproven for diagnosis of IBD, differentiating UC vs CD, or for management unless otherwise stated:

    Serologic markers labeled E/I: ASCA (anti-Saccharomyces cerevisiae antibodies); ANCA (anti-neutrophil cytoplasmic antibodies); ACCA (anti-chitobioside carbohydrate antibodies); ALCA (anti-laminaribioside carbohydrate antibodies); AMCA (anti-mannobioside carbohydrate antibodies); Anti-C (anti-chitin IgA); Anti-L (anti-laminarin IgA); OmpC (anti-outer membrane porin C antibodies); anti-Cbir1 (anti-Cbir1 flagellin antibodies); 12-antibody panels; Prometheus IBD sgi diagnostic test; and ASMA (for the indication of diagnosing IBD or distinguishing UC from Crohn's) are considered experimental/investigational for these indications.

    Listed as experimental/investigational for these indications; note ASMA may be medically necessary for autoimmune hepatitis diagnosis

    Therapeutic drug antibody/level tests labeled E/I: Measurement of antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab, and measurement of serum levels of these biologics (infliximab, adalimumab, vedolizumab, ustekinumab) are considered experimental/investigational for these indications. Named commercial assays (for example Anser IFX, Anser ADA, Anser VDZ, Anser UST) are included in tests considered experimental/investigational.

    Listed as experimental/investigational for measurement of therapeutic drug antibodies or drug levels for management of IBD

    Anti-smooth muscle antibodies (ASMA) are explicitly listed as experimental and investigational when used to diagnose inflammatory bowel disease or to distinguish ulcerative colitis from Crohn’s disease because their effectiveness for those indications has not been established. The policy notes that ASMA may be medically necessary for the separate indication of diagnosing autoimmune hepatitis, but not for IBD diagnostic differentiation.

    These extracted sections do not provide additional, test‑specific coverage criteria or exclusions beyond the policy statements; providers must follow applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and the health plan’s discretion for any indications not explicitly addressed in this policy. Reference the Medicare Benefit Policy Manual, Chapter 15 §50 and the CMS coverage database when Medicare rules apply.

    Serologic antibody panels including ASCA (anti‑Saccharomyces cerevisiae antibodies), ANCA (anti‑neutrophil cytoplasmic antibodies), and other listed markers (ACCA, ALCA, AMCA, Anti‑C, Anti‑L, OmpC, anti‑Cbir1, multi‑antibody panels, and Prometheus IBD sgi) are considered experimental, investigational, or unproven for the purposes of diagnosing IBD or distinguishing ulcerative colitis from Crohn’s disease. Likewise, measurement of antibodies to biologic therapies or measurement of serum drug levels and commercial assays (for example, Anser IFX, Anser ADA, Anser VDZ, Anser UST) are considered experimental/investigational for these diagnostic and management indications.

    No additional coverage notes are stated in the extracted sections for this placeholder. Where Medicare Part B rules or other NCDs/LCDs apply, follow those coverage and authorization requirements and any plan‑specific discretion for coverage decisions.

    Coding and Billing

    Covered CPT/HCPCS Codes when criteria metCPTCovered
    81401TPMT genetics (Molecular pathology procedure, Level 2); TPMT (thiopurine S-methyltransferase) gene analysis, common variants
    83630Lactoferrin, fecal; qualitative
    83631Lactoferrin, fecal; quantitative
    CPT/HCPCS Codes NOT coveredCPTNot Covered
    83789TPMT mass spectrometry and tandem mass spectrometry, qualitative or quantitative (listed as not covered)
    86256Fluorescent noninfectious agent antibody; titer, each antibody (listed as not covered)
    80299Quantification of therapeutic drug, not elsewhere specified (listed as not covered)
    82397Chemiluminescent assay (listed as not covered for listed antibody panels)
    83516Immunoassay for analyte other than infectious agent antibody or antigen (listed as not covered)
    83519Immunoassay, analyte, quantitative; not otherwise specified (RIA) (listed as not covered)
    83520Immunoassay, analyte, quantitative; not otherwise specified (listed as not covered)
    86021Antibody identification; leukocyte antibodies [ANCA antibodies] (listed as not covered)
    86255Fluorescent noninfectious agent antibody; screen, each antibody (listed as not covered)
    86671Antibody; fungus, not elsewhere specified (listed as not covered)
    1–10 of 13
    1/2
    Medicare Part B Covered Diagnosis Codes (not further specified)mixed
    Jurisdictions 5, 8Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD)
    Medicare Administrative Contractor jurisdictionsmixed
    F (2 & 3)MAC jurisdiction covering AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ; Contractor: Noridian Healthcare Solutions, LLC

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization documentation required

    Prior authorization requests must be accompanied by clinical documentation that supports medical necessity, including specialist chart notes, the ordering provider’s history & physical, results of colonoscopy and other diagnostic studies performed, and the pathology report.

    • Chart notes and history & physical from the ordering specialist
    • Results of colonoscopy and other diagnostic studies performed
    • Pathology report
    Note

    Plan discretion and NCD/LCD adherence

    Additional indications not explicitly listed in this policy may be covered at the discretion of the health plan. Where applicable, providers must follow any relevant National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for coverage and authorization rules.

    • Additional indications may be covered at plan discretion

    Background

    Inflammatory bowel disease (IBD) encompasses ulcerative colitis (UC) and Crohn’s disease (CD). Diagnosis is established primarily through radiographic, endoscopic, and histologic evaluation rather than by serologic testing. Serologic markers such as ANCA and ASCA have been investigated to assist in differentiating UC and CD but the policy states they lack sufficient established effectiveness for definitive diagnosis. In contrast, assessment of thiopurine metabolism is clinically relevant: TPMT genotype or phenotype testing is recommended prior to initiating azathioprine or 6‑mercaptopurine to determine candidacy and guide dosing (covered one time during the patient’s lifetime), and measurement of thiopurine metabolites is medically necessary when monitoring for suspected toxicity or lack of therapeutic response.

    Definitions

    TPMT testing — Tests assessing TPMT genotype or enzyme activity to determine candidacy and dosing for thiopurines.
    DefinitionTests assessing thiopurine S-methyltransferase (TPMT) genotype or enzyme activity to determine candidacy for and guide dosing of thiopurine drugs (azathioprine, 6-mercaptopurine, thioguanine).
    Covered indication (actionable)Baseline TPMT genotype testing is medically necessary to determine candidacy for thiopurine treatment prior to initiation of azathioprine, 6-mercaptopurine, or thioguanine and is covered one time during the patient’s lifetime.
    Monitoring indicationTPMT-related metabolite testing/thiopurine metabolite monitoring is medically necessary to evaluate suspected toxic responses (e.g., hepatotoxicity or myelotoxicity) or lack of therapeutic response while on therapy.
    Not covered/limited usesTPMT gene mutation assays and TPMT phenotypic assays are considered experimental and investigational for indications other than the listed baseline and monitoring uses.
    Relevant guidanceFDA recommends determination of TPMT (enzyme or genotype) prior to initiating azathioprine or 6-mercaptopurine; testing approaches apply regardless of testing laboratory.
    Policy Summary
    Payereocco
    PolicySerum Antibodies for Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2026
    Next Review DateJun 24, 2026
    Key ActionSubmit prior authorization with specialist chart notes, diagnostic study results, and pathology to support medical necessity.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and RequirementsBackgroundDefinitions
  1. Follow applicable NCDs and LCDs for coverage/authorization rules
  2. Step Therapy

    Step therapy not specified

    No step therapy requirements are specified in this policy for the tests and indications covered.

    Note

    Provider action (reserved)

    Reserved: no additional provider-action text was extracted for this item in the source materials.

    Documentation Required

    Information required with prior authorization

    Prior authorization requests must include supporting clinical records: specialist chart notes and history & physical, results of colonoscopy and other diagnostic studies performed, and the pathology report to substantiate the request.

    • Chart notes and history & physical from the ordering specialist
    • Results of colonoscopy and other diagnostic studies performed
    • Pathology report
    Denial Risk

    Denial risk for non‑covered indications

    Requests for testing that do not meet the policy’s medical necessity criteria — for example baseline TPMT testing or thiopurine metabolite monitoring when the listed indications are not met, or requests for tests designated experimental/investigational (such as ASCA or ANCA for IBD diagnosis) — may be denied.

    • Baseline TPMT testing must meet the covered indications (one-time baseline to determine candidacy prior to thiopurine initiation or in patients with abnormal CBC not responsive to dose reduction)
    • Thiopurine metabolite monitoring must meet the listed indications (suspected toxicity or lack of response)
    • Tests listed as experimental/investigational for IBD diagnosis or management (e.g., ASCA, ANCA) are subject to denial if requested for those indications
    Billing Rule

    NCD/LCD compliance required

    Claims and authorization requests must comply with any applicable NCDs and LCDs; failure to follow NCD/LCD requirements where they apply may result in claim denials or recoupment.

    • Comply with applicable National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs)
    • Noncompliance with NCD/LCD may lead to denial or recoupment
    Documentation Required

    Medicare documentation and NCD/LCD reference

    When Medicare guidance is relevant, providers should reference the Medicare Benefit Policy Manual, Chapter 15 §50 (Drugs and Biologicals) and any applicable NCDs/LCDs for outpatient (Part B) drugs and related coverage rules.

    • Medicare Benefit Policy Manual, Pub. 100-2, Chapter 15, §50
    • Check the CMS Medicare Coverage Database for applicable NCDs/LCDs
    Serum antibody panels (e.g., ASCA, ANCA) — Blood tests detecting ASCA and ANCA proposed for distinguishing UC vs CD or diagnosing IBD.
    DefinitionBlood tests detecting antibodies such as anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) proposed to assist in distinguishing Crohn’s disease from ulcerative colitis.
    Policy stanceUse of ASCA, ANCA, and other listed serologic antibody panels to diagnose IBD or to distinguish UC from Crohn’s disease is considered investigational/unproven and not medically necessary for those indications.
    Examples of panels/tests listed as E/IASCA, ANCA, ACCA, ALCA, AMCA, Anti-C, Anti-L, OmpC, anti-Cbir1, 12-antibody panels, Prometheus IBD sgi diagnostic test.
    Clinical noteAlthough ANCA and ASCA have been investigated (ANCA detected in 50-80% of UC; ASCA detected in 46-70% of CD), sensitivity is insufficient for definitive diagnosis or differentiation.
    ASCA / pANCA and other serologic markers — definitions and brief descriptions of serologic markers referenced in policy.
    ASCA (anti-Saccharomyces cerevisiae antibodies)Serologic marker studied for Crohn’s disease (detected in ~46-70% of CD patients; 6-12% of UC patients); listed as experimental/investigational for diagnosis or differentiation of IBD in this policy.
    pANCA / ANCA (perinuclear/anti-neutrophil cytoplasmic antibodies)Serologic marker more frequently detected in ulcerative colitis (ANCA detected in ~50-80% of UC and 10-40% of CD); considered insufficiently sensitive and listed as investigational for diagnostic use in this policy.
    Other named serologic markersACCA (anti-chitobioside), ALCA (anti-laminaribioside), AMCA (anti-mannobioside), Anti-C (anti-chitin IgA), Anti-L (anti-laminarin IgA), OmpC, anti-Cbir1 and broader multi-antibody panels are listed as experimental/investigational for IBD indications.
    Prometheus IBD sgi diagnostic testNamed commercial assay (Prometheus IBD sgi) is specifically listed as experimental/investigational for diagnosing or differentiating IBD in this policy.
    Evidence sourcesMultiple references cited supporting diagnostic investigations of these markers (see policy references).